Caribou Biosciences, Inc. layoffs
Yes. Caribou Biosciences, Inc. has filed 3 SEC 8-Ks with Item 2.05 (exit or disposal costs) since 2023. The most recent, on Oct 6, 2026, disclosed a workforce reduction.
Check CRBU layoff riskSEC filings since 2023
- Oct 62026
Caribou Biosciences discloses a workforce reduction
Caribou Biosciences, Inc. (CRBU) · filed 5 weeks agoOn October 2, 2026, the Board of Directors (the "Board") of Caribou Biosciences, Inc.
- Apr 242025
Caribou Biosciences discloses a workforce reduction
Caribou Biosciences, Inc. (CRBU) · filed 81 weeks agoOn April 24, 2025, the Company issued the Press Release announcing its strategic pipeline prioritization with workforce and cost reduction initiatives to focus resources on its lead oncology programs CB-010, an allogeneic anti-CD19 CAR-T cell therapy being evaluated in its ANTLER phase 1 clinical trial in patients with B cell non-Hodgkin lymphoma, and CB-011, an allogeneic anti-BCMA CAR-T cell therapy being…
- Jul 162024
Caribou Biosciences to cut about 21 jobs
Caribou Biosciences, Inc. (CRBU) · filed 121 weeks agoOn July 16, 2024, the Company discontinued preclinical research activities associated with its allogeneic CAR-NK platform and reduced its workforce by 21 positions, or approximately 12%.
Get this data via API
Pull layoff filings, risk scores, and WARN notices into your own product. Starts at $49/mo.